Estats Units - anglès - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in w

Estats Units - anglès - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - trifluoperazine hydrochloride (unii: 6p1y2snf5v) (trifluoperazine - unii:214izi85k3) - trifluoperazine 1 mg - for the management of schizophrenia. trifluoperazine hydrochloride tablets, usp are effective for the short-term treatment of generalized non-psychotic anxiety. however, trifluoperazine hydrochloride tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). when used in the treatment of non-psychotic anxiety, trifluoperazine hydrochloride tablets should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hydrochloride tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of trifluoperazine hydrochloride tablets as a treatment for non-psychotic anxiety was established in a 4-week clinical multicenter study of outpatients with generalized anxiety disorder (dsm-iii). this evidence does not predict that trifluoperazine hydrochloride tablets will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). trifluoperazine hydrochloride tablets have not been shown effective in the management of behavioral complications in patients with mental retardation. a known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and preexisting liver damage.

Estats Units - anglès - NLM (National Library of Medicine)

baxter healthcare corporation - prochlorperazine edisylate (unii: pg20w5vqzs) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine edisylate 5 mg in 1 ml - to control severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. do not use in patients with known hypersensitivity to phenothiazines. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in pediatric patients under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.

Estats Units - anglès - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in w

Estats Units - anglès - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 10 mg - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in w

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: citric acid; water for injections; sodium methyl hydroxybenzoate; disodium edetate; glycerol; sodium citrate dihydrate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; citric acid; sodium methyl hydroxybenzoate; glycerol; water for injections; disodium edetate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 2 mg/ml - oral liquid, solution - excipient ingredients: sodium methyl hydroxybenzoate; glycerol; sodium citrate dihydrate; water for injections; disodium edetate; citric acid - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: disodium edetate; glycerol; water for injections; sodium methyl hydroxybenzoate; citric acid; sodium citrate dihydrate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Estats Units - anglès - NLM (National Library of Medicine)

physicians total care, inc. - prochlorperazine (unii: yhp6ylt61t) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 25 mg - prochlorperazine 25 mg suppositories are indicated in the control of severe nausea and vomiting in adults. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in children under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.